Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ZYME - Zymeworks Inc. Latest News | Finranks

Home

ZYME

Z

Zymeworks Inc. (ZYME)

NMS – Real Time Price. Currency in USD

24.18

-0.51 (-2.07%)

At close: Mar 27, 2026, 4:00 PM EDT

24.18

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Needham 25th Annual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 15 at 10:15 am Eastern Time (ET). 2026 Bloom Burton & Co. Healthcare Investor Conference: Zymework's management will participate in one-on-one meetings and present on April 21 in Toronto, ON.

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company's partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera® (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. “We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR,” said Ken Galbraith, Chair, Chief Executive Officer, and Interim Chief Financial Officer of Zymeworks.

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego, CA.

Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

Zymeworks Inc. (ZYME) reported weak Q4 results, highlighting the volatility of its milestone-driven revenue model and underscoring execution risk ahead of commercialization. Despite top-line misses, ZYME improved FY25 profitability, narrowed net loss by 34%, and maintained strong liquidity with $270.6 million in cash and equivalents. The $250 million royalty-backed financing with Royalty Pharma extends ZYME's cash runway beyond 2028, reducing dilution risk but increasing dependence on Ziihera's commercial success.

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.31 per share a year ago.

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

Videos

No Data

There is no data to display

Press releases

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company's partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera® (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. “We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR,” said Ken Galbraith, Chair, Chief Executive Officer, and Interim Chief Financial Officer of Zymeworks.

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a summary of recent business highlights.

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company's corporate strategy announced in November.